

References

S-223

1. InterQual Level of Care Criteria 2017. Acute Care Adult. McKesson Health Solutions, LLC. 2017: ADLT-34.
2. Boston Medical Center. Sanchorawala V, Clinical Trials.gov. High-Dose Melphalan and Stem Cell Transplant in Treating Patients With Immunoglobulin Deposition Disease or Light-Chain Deposition Disease.
3. M.D. Anderson Cancer Center. Shah N. Clinical Trials.gov. Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients With Multiple Myeloma or Amyloidosis.
4. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Systemic Light-Chain Amyloidosis (V1.2018).
5. Roy V. Autologous Stem Cell Transplant for AL Amyloidosis. *Bone Marrow Research*. Vol. 2012. Article ID 238961.
6. Primary amyloidosis. MedlinePlus. Last updated 1/2013.
7. Gatt ME, Palladini G. Light Chain amyloidosis 2012: a new era. *British Journal of Haematology*. 2013 Jan 7;160(5):582-598.
8. Mahmood S, Palladini G, Sanchorawala V, Wechalekar. Update on treatment of light chain amyloidosis. *Haematologica*. 2014;99(2):211-221.
9. Sachchithanantham S, Offer M, Venner C, Mahmood S, et al. Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. *Haematologica*. 2015;100(11):1469-1476.
10. Banypersad S, Moon J, Whelan C, et al. Updates in cardiac amyloidosis: A review. *J Am Heart Assoc*. 2012. (2):1-13.
11. Dipenzieri A, Buadi, Kumar S, Reeder C, et al. Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) Consensus Statement. Mayo Clinic. 2015;90(8):1054-1081.
12. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. Nov 2015;21(11):1863-1869.
13. Tsukada N, Ikeda M, Suzuki K, et al. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases. *International Journal Of Hematology*. March 2016;103(3):299-305.
14. Hayashi T, Ikeda H, Shinomura Y, et al. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP. *International Journal Of Hematology*. December 2014;100(6):554-558.
15. Muchtar E, Buadi F, Dispenzieri A, Gertz M. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. *Acta Haematologica*. 2016;135(3):172-190.
16. Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. *Br J Haematol*. Jan 2015;168(2):186-206.

17. Rajkumar SV. Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases. In: Glasscock RJ, Kyle RA, Schwab SJ, eds. Up-To-Date Online 2017.